Jeff Hall

Two-thirds of men with a positive screening MRI for prostate cancer had PSA levels below 3 ng/mL and 91 percent of these men had clinically significant prostate cancer, according to newly published research.

Primary diagnostic delays in mammography screening led to a greater than 10 percent higher incidence of lymph node metastasis with invasive breast cancer in comparison to women without a primary diagnostic delay, according to new research out of the Netherlands.

In interviews at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, researchers discussed the potential impact of ultra-high resolution brain positron emission tomography (PET) as well as emerging PET radiotracers for detecting coronary artery disease in obese patients and diagnosing clear cell renal cell carcinoma.

The artificial intelligence (AI)-enabled VisiRad XR reportedly demonstrated an 83 percent sensitivity rate for detecting lung nodules and masses on chest X-rays in one retrospective study.

For patients 80 years of age or older that have a PSA level at 20 ng/mL or higher, PSMA PET/CT has a high likelihood of success in diagnosing and staging prostate cancer regardless of pre-imaging biopsy use, according to newly published research.

In an analysis of patients with intraprostatic/prostate bed findings of biochemical prostate cancer recurrence, the use of 18F-DCFPyL PET/CT led to an 82.3 percent cancer detection rate in comparison to 80 percent for multiparametric MRI, according to research presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.

In a new study comparing standard breast MRI, abbreviated breast MRI and contrast-enhanced mammography in supplemental breast cancer screening, researchers found that MRI offered a greater than 14 percent higher cancer detection rate and a nearly 39 percent higher sensitivity rate than CEM.

The De Novo approval for Viz HCM, which assesses electrocardiograms with artificial intelligence (AI) to identify possible cases of hypertrophic cardiomyopathy (HCM), is the 12th FDA clearance of algorithms on the Viz.ai Platform.

In the first episode of a three-part series, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss recently issued updates to breast cancer screening recommendations from the American College of Radiology and the United States Preventive Services Task Force and potential implications for health equity.

In a recent study examining neuroimaging biomarkers of Alzheimer’s disease, researchers found that neocortical tau pathology exhibited the strongest association with cognitive decline and the use of tau positron emission tomography (tau-PET) provided the best prognostic value of all neuroimaging modalities in this patient population.

The use of non-contrast, biparametric MRI (bpMRI) for prostate cancer screening regardless of PSA values detected more clinically significant cases of prostate cancer than reserving bpMRI for patients with elevated PSA levels, according to preliminary findings from an ongoing prospective, randomized study.

Through a new technology add-on payment (NTAP), the use of Cytalux will reportedly be reimbursed by CMS up to 65 percent of the cost of the molecular imaging agent, which is FDA-approved for intraoperative imaging of ovarian and lung cancer.

Emerging research suggests that a high volume of enhancing parenchyma on dynamic contrast-enhanced MRI more than doubles the breast cancer risk for women with extremely dense breasts.

The most common brain MRI findings associated with COVID-19 included acute/subacute infarction in 22 percent of patients and cerebral microbleeds in 17 percent of patients.

The indications for Gadobutrol injection, a generic substitute for Gadavist, include neurovascular and cardiovascular assessments as well as breast malignancy detection with magnetic resonance imaging (MRI).

In a video interview, Hong Song, M.D., Ph.D., discussed retrospective research, presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, that evaluated the combination of artificial intelligence (AI)-based software and the PSMA agent piflufolastat F 18 to help quantify prostate cancer lesions and associations with biochemical progression-free survival.

The controversial Independent Dispute Resolution (IDR) process of the No Surprises Act was temporarily suspended by the CMS on August 4 due to a federal court ruling that vacated a substantial administrative fee increase and batching rule from the CMS that reportedly curtailed challenges of claim reimbursement by radiologists and other providers.

The PET radiotracer 18F-PSMA-1007 facilitated detection of at least one suspicious lesion for metastasis in nearly half of a cohort of 160 patients with prostate cancer, according to research presented recently at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.

In what may represent the first CMS approval of a new technology add-on payment (NTAP) for an artificial intelligence (AI)-based heart failure detection platform, use of the EchoGo Heart Failure system will be eligible for up to $1,023.75 in NTAP reimbursement per acute hospital in-patient stay as of October 1, 2023.

Emerging research suggests that achieving an optimal virtual monoenergetic image (VMI) energy level with photon-counting computed tomography (CT) may allow up to a 40 percent reduction of contrast media dosing for coronary CT angiography.

With reported performance validation on over 17,000 ultrasound images, Sonio Detect employs artificial intelligence (AI) to help ensure quality criteria for fetal ultrasound imaging of the brain and heart.

Reportedly the first randomized trial to examine the impact of artificial intelligence (AI) on screening mammography, researchers found AI-aided screening led to a 20 percent increase in breast cancer detection and a 44.3 percent decrease in mammography screening workload.

Through automated processing of diffusion-weighted magnetic resonance imaging (MRI) scans, the Advanced Neuro Diagnostic Imaging (ANDI) software performs detailed analysis of white matter microstructure.

In a study of 413 men with suspected prostate cancer, researchers found the combination of ultrasound and multiparametric MRI-targeted biopsy with systematic biopsy diagnosed prostate cancer in 72.9 percent of patients in comparison to 60.2 percent with systematic biopsy alone.

Full Brain Solution is reportedly the only artificial intelligence (AI)-enabled software that facilitates detection of medium vessel occlusions (MeVOs) as well as anterior and posterior large vessel occlusions (LVOs) on computed tomography (CT) exams.

In a study of over 1.300 women with dense breasts, the combination of mammography and ultrasound had a recall rate of 11.7 percent, a specificity rate of 89.1 percent and an accuracy rate of 89.2 percent in comparison to a 21.4 percent recall rate, 79.4 percent specificity and 79.5 percent accuracy for the combination of mammography, ultrasound, and artificial intelligence (AI).

Indicated for use in two-dimensional transthoracic echocardiography (2D-TTE) in adults, the AI Guidance software reportedly enables novice ultrasound users to obtain real-time cardiac imaging at the point of care.

In a study of 601 patients with prostate cancer, researchers found that only one patient with extensive metastasis was falsely diagnosed as non-metastatic on whole-body, low-dose computed tomography (CT) by reviewing radiologists.

In a dataset enriched for African American women, BRCA mutation carriers and those with benign breast disease, a mammography-based deep learning model demonstrated a five-year AUC of 63 percent for predicting breast cancer in comparison to 54 percent for BI-RADS assessment.

In a study of over 20,700 people, researchers found that artificial intelligence (AI) analysis of body composition measurements via lung cancer screening computed tomography (CT) exams improves the prediction of mortality risks for lung cancer, cardiovascular disease, and all-cause mortality.